Accuray Inc (NASDAQ:ARAY) (TREND ANALYSIS) reported last earnings figures on January 27th. The company announced actual earnings per share of $-0.13 against the consensus Street estimate of $-0.08. This represents a year-on-year decrease of earning per share of $-0.06 from corresponding quarter of last year. Accuray Inc posted revenue of $98.16 million versus estimate of $61.16 million.
Stock Performance: Click here for a free comprehensive Trend Analysis Report
Accuray Inc (NASDAQ:ARAY) is currently trading 36.04% below its 52-week-high, 15.86% above its 52-week-low and in the range of $6.36-$7.64 over the past month. The 1-year range for the stock is $5.99-$10.85. Accuray Inc (ARAY) has a price to book ratio of 7.11 versus Nasdaq average of 4.52. The company’s share price has under-performed the Nasdaq year to date by -6.75%.
The company is currently valued at $540.28 million and closed the last trading session at $6.94. The stock has 50-day moving average of $7.02 and a 200-day moving average of $7.81.
Accuray Inc (ARAY) current short interest stands at 15,633,724 shares. It has decreased by 3% from the same period of last month. Around 20.8% of the company’s shares, which are float, are short sold. With a 30-days average daily volume of 884,674 shares, the number of days required to cover the short positions stand at 14.4 days.
Is this a Buying Opportunity? Click here for a free Trend Analysis Report
There are currently ten analysts that we track that cover ARAY. Of those ten, six have a buy rating, three have a hold rating, and one has a sell rating. On a consensus basis this yields to a score of 3.9 and a Buy. The consensus target price stands at $10.59 which represents an upside of 52.65% from the last closing price of $6.94.
The most recent analyst activity consisted of Brean Capital LLC reiterating their buy stance with a target price of $12, which represents an upside of 72.91% from the last closing price. On the date of report, the stock closed at $6.94.
Another research firm weighing in recently was JPMorgan maintaining their overweight stance with a target price of $12, which corresponds to an upside of 72.91% from the last closing price. On the date of report, the stock closed at $6.94.
A third research firm weighing in recently was Northland Securities Inc initiating coverage at outperform with a target price of $11, which translates into an upside of 58.5% from the last closing price. On the day of report, the stock closed at $6.92.
Accuray Inc. develops medical equipment. The Company produces radiation therapy and radiosurgery treatment systems. Accuray Inc. has developed an intelligent robotic radio surgery system designed to treat solid tumors anywhere in the body as an alternative to traditional surgery.